News Surmodics, Inc.

Equities

SRDX

US8688731004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
26.49 ^USD	+0.38%		-1.89%	-27.13%

Feb. 06	Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating	MT
Feb. 01	Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1	Apr. 19	BU
Surmodics to Participate in Upcoming Investor Conferences in March and April	Feb. 27	BU
Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating	Feb. 06	MT
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results, Updates Fiscal Year 2024 Financial Guidance	Feb. 02	AQ
Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating	Feb. 01	MT
Surmodics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 01	CI
Transcript : Surmodics, Inc., Q1 2024 Earnings Call, Feb 01, 2024	Feb. 01
(SRDX) SURMODICS Forecasts Fiscal Year 2024 Revenue Range $117M - $121M	Feb. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 Revenue $30.6M, vs. Street Est of $29.6M	Feb. 01	MT
Earnings Flash (SRDX) SURMODICS Reports Q1 EPS $0.00, vs. Street Est of $-0.30	Feb. 01	MT
SurModics: Fiscal Q1 Earnings Snapshot	Feb. 01	AQ
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance	Feb. 01	BU
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 01	CI
Surmodics Announces Successful Early Clinical Use of Pounce LP Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli below the Knee	Jan. 23	AQ
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee	Jan. 22	BU
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System	Jan. 22	CI
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1	Jan. 16	BU
Surmodics to Host Virtual Annual Meeting of Shareholders	Jan. 16	BU
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium	Nov. 16	BU
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium	Nov. 16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Surmodics, Inc.

Equities

SRDX

US8688731004

Summary

Filters